Our cancer research examines many of the most prevalent cancers today with the goal of finding new and innovative therapies, treatments and ultimately prevention and cures.
Our researchers discovered a link between finasteride, a medication used to relieve urinary problems, and prevention of prostate cancer.
The UT Health San Antonio Cancer Center is a member of The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC).
UT Health San Antonio studies cancers in women, men and children, including: breast cancer, cancers of the brain and nervous system, Hodgkin’s Lymphoma, leukemia, prostate cancer, ovarian cancer, melanoma and cancers affecting various organs and multiple sites. Many studies are conducted at UT Health Cancer Center and at our Greehey Children’s Cancer Research Institute.
UT Health San Antonio led a groundbreaking clinical trial, treating glioblastomas (the deadliest of brain tumors) with tiny radioactive fat particles, only 100 nanometers across, inserted directly into the tumor.
There is much to gain by having The University of Texas Health Science Center and MD Anderson, the top-ranked cancer-treatment hospital in the country, collaborate on expanding the services available in San Antonio.
UT Health San Antonio and UT Health Houston announced agreements June 23 to grant exclusive global licenses for two unique biologic therapeutics to AlaMab Therapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd. The biologics will be developed into novel, first-in-class therapies for spinal cord injury and breast cancer bone metastasis.